Va. AG appeals healthcare reform decision to Supreme Court

Virginia Attorney General Ken Cuccinelli has filed an appeal in the U.S. Supreme Court regarding its challenge to the Patient Protection and Affordable Care Act (PPACA).

Virginia's petition asks the Supreme Court to overturn the recent decision of the U.S. Fourth Circuit Court of Appeals that dismissed Virginia's lawsuit because the court said the commonwealth lacked standing to challenge the healthcare law. Cuccinelli is defending the Virginia HealthCare Freedom Act (VHCFA), which the Virginia General Assembly passed that states that no one can force Virginia citizens to purchase health insurance.

"The court's decision is not only in conflict with the Constitution, but it is also in direct conflict with the decisions of the Supreme Court and of numerous other circuit courts of appeals,” Cuccinelli stated. “In fact, neither the federal government in its arguments nor the Fourth Circuit in its opinion identified a single case where the Supreme Court or another federal circuit court had ever found that a state lacked standing to defend a statute from a claim of federal preemption."

Cuccinelli wishes to raise a second issue by asking the Supreme Court to review the case on the merits of whether or not Congress has the ability to mandate that individuals purchase health insurance.

"Given the importance of the issue, we believe that multiple petitions should be granted to guarantee that the Supreme Court has a case in which it can reach all the key constitutional questions,” Cuccinelli concluded. “In its filings in the Supreme Court, the federal government has raised the possibility that the other suits may not have standing and may be barred by the federal Anti-Injunction Act. Accordingly, because Virginia's is the case in which the issue of state sovereign standing has been most fully developed, it may be the only case where the court can reach the merits of all the constitutional questions this law has created.”

Recently, President Barack Obama asked the Supreme Court to hear a case concerning the constitutionality of the PPACA. 

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.